Comparative Pharmacology
Head-to-head clinical analysis: CHOLEDYL versus THEOPHYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLEDYL versus THEOPHYL.
CHOLEDYL vs THEOPHYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choledyl is a salt of theophylline (1,3-dimethylxanthine) and choline. Theophylline acts as a bronchodilator by inhibiting phosphodiesterase (PDE) and antagonizing adenosine receptors, resulting in increased intracellular cAMP and smooth muscle relaxation. It also enhances respiratory drive and diaphragm contractility.
Theophylline is a methylxanthine that causes bronchodilation primarily through inhibition of phosphodiesterase (PDE) and antagonism of adenosine receptors. It also has mild anti-inflammatory effects and enhances mucociliary clearance.
200-400 mg orally 4 times daily, not to exceed 2.4 g/day; or as sustained-release tablets: 400-600 mg twice daily.
300 mg orally every 6 hours or 400-600 mg extended-release orally every 12-24 hours; intravenous loading dose 5-6 mg/kg over 20-30 minutes, then continuous infusion 0.4-0.6 mg/kg/h
None Documented
None Documented
Clinical Note
moderateTheophylline + Gatifloxacin
"The metabolism of Gatifloxacin can be decreased when combined with Theophylline."
Clinical Note
moderateTheophylline + Rosoxacin
"The metabolism of Rosoxacin can be decreased when combined with Theophylline."
Clinical Note
moderateTheophylline + Levofloxacin
"The metabolism of Levofloxacin can be decreased when combined with Theophylline."
Clinical Note
moderateTheophylline + Trovafloxacin
Terminal elimination half-life: 7-9 hours (non-smoking adults); 4-5 hours (smokers); 20-30 hours (premature neonates, hepatic cirrhosis, CHF); clinical context: dose adjustment required for smokers and hepatic impairment.
Terminal elimination half-life: Adults nonsmokers: 6–12 h (mean 8.7 h); adult smokers: 4–5 h; children: 3–5 h; neonates: 20–30 h; hepatic cirrhosis: up to 30 h. Half-life increases with congestive heart failure, fever, and concurrent CYP1A2 inhibitors (e.g., cimetidine, fluvoxamine).
Primarily renal excretion of theophylline metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid), with 10% unchanged drug; biliary/fecal < 5%.
Renal: 10% unchanged in adults (higher in neonates). Hepatic metabolism to inactive metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid) excreted renally; fecal excretion <5%.
Category C
Category C
Bronchodilator
Bronchodilator
"The metabolism of Trovafloxacin can be decreased when combined with Theophylline."